The kidney disease market is expected to reach US$ 133,444.71 million by 2027 from US$ 81,128.11 million in 2019. The market is estimated to grow with a CAGR of 6.5% from 2020 to 2027.
Policy-makers have to ensure that an appropriate mix of pharmaceutical policy options is implemented to meet equitable, affordable, and sustainable access to medicines as well as medical care. The World Health Organization has projected various strategies to support policy-makers in developing suitable policies, including the concept of the vital medicine list and the universal health coverage (UHC) approach. Moreover, European countries with advanced UHC and social protection systems have developed pharmaceutical pricing and reimbursement systems that intend to offer various crucial medicines to their citizens at no or reduced cost. For instance, Armenia ensures 100% reimbursement for medicines for specific diseases such as TB, mental health diseases, diabetes, and chronic kidney failure.
Request for sample @ https://www.theinsightpartners.com/sample/TIPRE00014589/
Based on product type, the kidney disease market is segmented into diagnosis and treatment. In 2019, the diagnosis segment accounted for the largest share of the market. Growth of this segment is attributed to increase inblood tests, urine tests, and different imaging procedures.
According to the estimates given by the Centers of Disease Control and Prevention (CDC) in 2020, 1 in 3 adults with diabetes and 1 in 5 adults with high blood pressure might have chronic kidney disease. In 2015, 30.3 million people in the US had diabetes as per the American Diabetes Association. According to the CDC, in 2014, around 118,000 people in the US started the treatment for end-stage renal disease, and the number of people taking this treatment is expected to increase as more people become aware of this condition. Moreover, the CDC states that around 96% of the people with kidney damage are not aware of having chronic kidney disease, which indicates the underlying market prospective in the kidney disease market. These factors are expected to enhance market growth during the forecast period.
Chronic kidney disease (CKD) is a common and life-threatening condition that affects 1 in 10 people worldwide. High blood pressure and diabetes were the two major causes in 75% of kidney failure cases between 2015 and 2017. Moreover, according to a study published by National Kidney Foundation in 2020, around 35.0% of the diabetic population above age 20 years would develop chronic kidney disease over the period of time.
As per the data published by National Kidney Foundation Inc., in 2020, CKD is likely to cause more deaths than prostate cancer or breast cancer. It is an under-recognized emergency health condition among people. 1 in 3 American adults (about 80 million people) is at risk due to CKD.
An outline of the regional analysis:
Additional highlights of the Kidney Disease market report:
Purchase This Report at: https://www.theinsightpartners.com/buy/TIPRE00014589/
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.